Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1117 ARTÍCULOS , VIENDO DEL 916 AL 930

Periventricular diffusivity reflects APOE ε4-modulated amyloid accumulation and cognitive impairment in the Alzheimer's disease continuum

Chen CL, Son SJ, Schweitzer N, Jin H, Li J, Wang L, Yang S, Hong CH, Roh HW, Park B, Choi JW, An YS, Seo SW, Cho YH, Hong S, Nam YJ, Minhas DS, Laymon CM, Stetten GD, Tudorascu DL, Aizenstein HJ, Wu M; Mayo Clinic Study of Aging.

Alzheimers Dement. 2025 Sep;21(9):e70659. doi: 10.1002/alz.70659.

Effects of intermittent theta-burst stimulation on cognition and glymphatic system activity in mild cognitive impairment and very mild Alzheimer's disease: a randomized controlled trial

Yang CC, Huang KY, Hsu JL, Hu CJ, Lu YH, Kuan YC.

J Neuroeng Rehabil. 2025 Sep 26;22(1):195. doi: 10.1186/s12984-025-01738-1.

Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer's disease

Kim HB, Yoo S, Kwak H, Ma SX, Kim R, Lee M, Ha N, Pyo S, Kwon SG, Cho EH, Lee SM, Jang J, Kim WK, Park HC, Baek M, Park Y, Park JY, Park JW, Hwang SW, Hwang JI, Seong JY.

Alzheimers Res Ther. 2025 Jul 21;17(1):168. doi: 10.1186/s13195-025-01813-8.

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, Doherty T, Tian L, Raman R, Aisen PS, Kramer LD, Irizarry MC, Dhadda S.

Alzheimers Dement. 2025 Sep;21(9):e70702. doi: 10.1002/alz.70702.

Computerized cognitive training enhances cognitive function in Alzheimer's disease by downregulating Ruminococcus-TMAO pathway

Zhang W, Song J, Zhong F, Yu W, Qin Z, Yang Z, Liu J, Wang X, Chen L, Lü W, Xing D, Liu J, Huang C, Wu J, Liu X, Yu W, Lü Y.

J Transl Med. 2025 Oct 24;23(1):1173. doi: 10.1186/s12967-025-07209-4.

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition

Liu Y, Fowler H, Wang DD, Barnes LL, Cornelis MC.

Nutrients. 2025 Aug 4;17(15):2548. doi: 10.3390/nu17152548.

Retinal vascular alterations in cognitive impairment: A multicenter study in China

Shi Q, Ni A, Li K, Su W, Xie W, Zheng H, Wang M, Xiao Z, Wu W, Shi K, Zhang P, Yan B, Ding D, Kwok T, Zhao Q, Zhang J.

Alzheimers Dement. 2025 Feb;21(2):e14593. doi: 10.1002/alz.14593.

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.

Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776.

Synapse vulnerability and resilience across the clinical spectrum of dementias

Taddei RN, Duff KE.

Nat Rev Neurol. 2025 Jul;21(7):353-369. doi: 10.1038/s41582-025-01094-7. Epub 2025 May 22.

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis

Hsu CW, Hsu TW, Kao YC, Lin YH, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Yang FC, Tsai CK, Yu CL, Tu YK, Liang CS.

J Prev Alzheimers Dis. 2025 Sep;12(8):100195. doi: 10.1016/j.tjpad.2025.100195. Epub 2025 May 1.

Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia

Nakamura Y, Adachi J, Hirota N, Iba K, Sasajima C, Shimizu K, Nakai M, Takahashi K.

Alzheimers Dement. 2025 Jul;21(7):e70522. doi: 10.1002/alz.70522.

Donanemab for Alzheimer's disease: from preclinical research to the clinical application

Dodel R, Frölich L.

Expert Rev Neurother. 2025 Oct;25(10):1151-1163. doi: 10.1080/14737175.2025.2546868. Epub 2025 Aug 25.

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial

Rajji TK, Baksh SN, Shade DM, Ismail Z, Burhan AM, Okhravi HR, Padala PR, Rosenberg PB, Schneider LS, Porsteinsson AP, Lyketsos CG; S-CitAD Research Group.

Nat Med. 2025 May;31(5):1586-1591. doi: 10.1038/s41591-025-03569-y. Epub 2025 Mar 25.

White Matter Abnormalities and Cognition in Aging and Alzheimer Disease

Peter C, Sathe A, Shashikumar N, Pechman KR, Workmeister AW, Jackson TB, Huo Y, Mukherjee S, Mez J, Dumitrescu LC, Gifford KA, Bolton CJ, Gaynor LS, Risacher SL, Beason-Held LL, An Y, Arfanakis K, Erus G, Davatzikos C, Tosun-Turgut D, Habes M, Wang D, Toga AW, Thompson PM, Zhang P, Schilling KG, Albert M, Kukull W, Biber SA, Landman BA, Bendlin BB, Johnson SC, Schneider J, Barnes LL, Bennett DA, Jefferson AL, Resnick SM, Saykin AJ, Crane PK, Cuccaro ML, Hohman TJ, Archer DB; and the Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC) Analyst Team; Zaras D, Yang Y, Durant A, Kanakaraj P, Kim ME, Gao C, Newlin NR, Ramadass K, Khairi NM, Li Z, Yao T, Choi SE, Klinedinst B, Lee ML, Scollard P, Trittschuh EH, Sanders EA.

JAMA Neurol. 2025 Aug;82(8):825-836. doi: 10.1001/jamaneurol.2025.1601. Epub 2025 Jun 9.

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity

Moscoso A, Heeman F, Raghavan S, Costoya-Sánchez A, van Essen M, Mainta I, Camacho V, Rodríguez-Fonseca O, Silva-Rodríguez J, Perissinotti A, Gu Y, Yun J, Peretti D, Ribaldi F, Coomans EM, Brum WS, Grothe MJ, Aguiar P, Bischof GN, Drzezga A, Seo SW, Villeneuve S, Malpetti M, O'Brien JT, Rowe JB, van de Giessen EM, Ossenkoppele R, Jagust WJ, Smith R, Hansson O, Frisoni GB, Garibotto V, Soleimani-Meigooni DN, Carrillo M, Dickerson BC, La Joie R, Rabinovici GD, Apostolova LG, LaMontagne PJ, Pontecorvo MJ, Johnson KA, Sperling RA, Weiner MW, Petersen RC, Jack CR Jr, Vemuri P, Schöll M; PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2025 Jul 15;334(3):229-242. doi: 10.1001/jama.2025.7817.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias